Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD4H6V
|
|||
| Drug Name |
BI 1206
|
|||
| Drug Type |
Antibody
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1/2 | [1] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | ||
| leukaemia [ICD-11: 2A60-2B33; ICD-10: C91-C95; ICD-9: 204-208] | Phase 1/2 | [1] | ||
| Company |
BioInvent
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin gamma Fc receptor IIB (FCGR2B) | Target Info | . | [2] |
| KEGG Pathway | Phagosome | |||
| Osteoclast differentiation | ||||
| B cell receptor signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Staphylococcus aureus infection | ||||
| Tuberculosis | ||||
| Measles | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| BCR signaling pathway | ||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02933320) BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BioInvent. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.